Castle Biosciences' Common Equity rose 589.29% to $467.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $467.0 million, marking a year-over-year increase of 589.29%. This contributed to the annual value of $455.8 million for FY2024, which is 1650.17% up from last year.
According to the latest figures from Q3 2025, Castle Biosciences' Common Equity is $467.0 million, which was up 589.29% from $455.4 million recorded in Q2 2025.
In the past 5 years, Castle Biosciences' Common Equity ranged from a high of $467.0 million in Q3 2025 and a low of $378.8 million during Q2 2023
Its 5-year average for Common Equity is $416.6 million, with a median of $411.7 million in 2021.
Its Common Equity has fluctuated over the past 5 years, first soared by 37602.41% in 2021, then plummeted by 1017.22% in 2023.
Quarter analysis of 5 years shows Castle Biosciences' Common Equity stood at $411.7 million in 2021, then fell by 3.06% to $399.2 million in 2022, then decreased by 1.97% to $391.3 million in 2023, then rose by 16.5% to $455.8 million in 2024, then grew by 2.46% to $467.0 million in 2025.
Its Common Equity was $467.0 million in Q3 2025, compared to $455.4 million in Q2 2025 and $440.3 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value